Dominika Kędzia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dominika Kędzia has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Oliwia Gawlik-Kotelnicka
Department of Affective and Psychotic Disorders, Medical University of Lodz, Czechoslowacka 8/10, 92-216 Lodz, Poland
2 shared publications - Aleksandra Margulska
Department of Child and Adolescent Psychiatry, Medical University of Lodz, Czechoslowacka 8/10, 92-216 Lodz, Poland
1 shared publication - Dominik Strzelecki
Department of Affective and Psychotic Disorders, Medical University of Lodz, Czechoslowacka 8/10, 92-216 Lodz, Poland
1 shared publication - Ewelina Barszcz
Central Teaching Hospital, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland
1 shared publication - Grzegorz Galita
Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland
1 shared publication - Ireneusz Majsterek
Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland
1 shared publication
Latest Publications
- Open Access
- 7 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3582
Depressive and Anxiety Symptoms in Women with Polycystic Ovary Syndrome: A Meta-Analysis
Background/Objectives: Polycystic ovary syndrome (PCOS) is the most commonly diagnosed endocrine disorder in women of reproductive age, with a prevalence estimated at 4–20%. Among the conditions often co-occurring with PCOS are depressive and anxiety disorders. The aim of this study was to determine the prevalence of depressive and anxiety symptoms in women with PCOS. Methods: A literature search was conducted using PubMed/MEDLINE, Google Scholar, and Directory of Open Access Journals databases for studies published before May 2025. The analysis was conducted on a group of 5857 women (study group: 3610; control group: 2247) obtained from 35 studies, which met the inclusion criteria. Results: The prevalence of depressive symptoms in PCOS patients and the controls, according to the BDI, HADS-D, Mini-NPI and PHQ assessment tool, was 42.11% (95% CI: 32.6–52.2) vs. 13.62% (95% CI: 8.4–21.5; p < 0.001); 28.90% (95% CI: 20.7–38.8) vs. 15.80% (95% CI: 11.3–21.7; p = 0.010); 59.10% (95% CI: 30.9–82.4) vs. 65.90% (95% CI: 24.2–92.1; p = 0.792); and 26.50% (95% CI: 8.0–59.9) vs. 9.10% (95% CI: 1.8–35.1; p = 0.255). The prevalence of anxiety symptoms in the PCOS group and the control group, according to the HADS-A assessment tool, was 48.25% (95% CI: 36.1–60.6) vs. 31.40% (95% CI: 18.8–47.4; p = 0.098), respectively. Conclusions: The study confirms the higher prevalence of depressive symptoms in women with PCOS compared to the general population. These findings indicate the necessity of conducting psychiatric examinations and providing support for women with PCOS.
- 7 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3582
Open AccessDepressive and Anxiety Symptoms in Women with Polycystic Ovary Syndrome: A Meta-Analysis
Background/Objectives: Polycystic ovary syndrome (PCOS) is the most commonly diagnosed endocrine disorder in women of reproductive age, with a prevalence estimated at 4–20%. Among the conditions often co-occurring with PCOS are depressive and anxiety disorders. The aim of this study was to determine the prevalence of depressive and anxiety symptoms in women with PCOS. Methods: A literature search was conducted using PubMed/MEDLINE, Google Scholar, and Directory of Open Access Journals databases for studies published before May 2025. The analysis was conducted on a group of 5857 women (study group: 3610; control group: 2247) obtained from 35 studies, which met the inclusion criteria. Results: The prevalence of depressive symptoms in PCOS patients and the controls, according to the BDI, HADS-D, Mini-NPI and PHQ assessment tool, was 42.11% (95% CI: 32.6–52.2) vs. 13.62% (95% CI: 8.4–21.5; p < 0.001); 28.90% (95% CI: 20.7–38.8) vs. 15.80% (95% CI: 11.3–21.7; p = 0.010); 59.10% (95% CI: 30.9–82.4) vs. 65.90% (95% CI: 24.2–92.1; p = 0.792); and 26.50% (95% CI: 8.0–59.9) vs. 9.10% (95% CI: 1.8–35.1; p = 0.255). The prevalence of anxiety symptoms in the PCOS group and the control group, according to the HADS-A assessment tool, was 48.25% (95% CI: 36.1–60.6) vs. 31.40% (95% CI: 18.8–47.4; p = 0.098), respectively. Conclusions: The study confirms the higher prevalence of depressive symptoms in women with PCOS compared to the general population. These findings indicate the necessity of conducting psychiatric examinations and providing support for women with PCOS.
- Open Access
- 12 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1451
Postnatal Bonding in the First Year After Birth: The Role of Maternal Depression, Resilience, and Anxiety During the COVID-19 Pandemic and War-Related Stress—A Prospective Cohort Study
Background: Postnatal bonding reflects the early emotional relationship between a mother and her infant and is shaped by psychological and perinatal factors. This study examined associations between postnatal bonding and maternal depressive symptoms, resilience, labor anxiety, and sociodemographic and health-related variables, as well as anxiety related to the COVID-19 pandemic, the war in Ukraine, and global events. Methods: This prospective cohort study included and followed 150 pregnant women in Poland from pregnancy to 12 months postpartum. Assessments were conducted during pregnancy and at 4–6 weeks, 6 months, and 12 months after delivery. Postnatal bonding was assessed using the PBQ, depressive symptoms with the EPDS, labor anxiety with the LAQ, resilience with the KOP-26, and anxiety related to external stressors with study-specific questionnaires. Non-parametric analyses were performed with a significance level of p < 0.05. Results: Postnatal bonding difficulties were most prevalent at 4–6 weeks postpartum (26.1%) and decreased over time. Maternal depressive symptoms showed the strongest and most consistent associations with bonding difficulties, whereas higher resilience, particularly in family relations and social competence, was associated with better bonding outcomes. Labor anxiety was weakly associated with bonding only in the early postpartum period, while no associations were found with sociodemographic characteristics or anxiety related to external societal stressors. Conclusions: Maternal depressive symptoms and resilience emerged as the key factors associated with postnatal bonding quality, highlighting their importance as targets for early identification and intervention.
- 12 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1451
Open AccessPostnatal Bonding in the First Year After Birth: The Role of Maternal Depression, Resilience, and Anxiety During the COVID-19 Pandemic and War-Related Stress—A Prospective Cohort Study
Background: Postnatal bonding reflects the early emotional relationship between a mother and her infant and is shaped by psychological and perinatal factors. This study examined associations between postnatal bonding and maternal depressive symptoms, resilience, labor anxiety, and sociodemographic and health-related variables, as well as anxiety related to the COVID-19 pandemic, the war in Ukraine, and global events. Methods: This prospective cohort study included and followed 150 pregnant women in Poland from pregnancy to 12 months postpartum. Assessments were conducted during pregnancy and at 4–6 weeks, 6 months, and 12 months after delivery. Postnatal bonding was assessed using the PBQ, depressive symptoms with the EPDS, labor anxiety with the LAQ, resilience with the KOP-26, and anxiety related to external stressors with study-specific questionnaires. Non-parametric analyses were performed with a significance level of p < 0.05. Results: Postnatal bonding difficulties were most prevalent at 4–6 weeks postpartum (26.1%) and decreased over time. Maternal depressive symptoms showed the strongest and most consistent associations with bonding difficulties, whereas higher resilience, particularly in family relations and social competence, was associated with better bonding outcomes. Labor anxiety was weakly associated with bonding only in the early postpartum period, while no associations were found with sociodemographic characteristics or anxiety related to external societal stressors. Conclusions: Maternal depressive symptoms and resilience emerged as the key factors associated with postnatal bonding quality, highlighting their importance as targets for early identification and intervention.
- Top Cited PapersOpen Access
- 15 January 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (1) , 156
Microglia, Astrocytes, and Oligodendrocytes in Parkinson’s Disease: Neuroinflammatory Crosstalk and Emerging Therapeutic Strategies
Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by the degeneration of dopaminergic neurons in the substantia nigra, resulting in cardinal motor symptoms such as tremor, rigidity, and bradykinesia. Neuroinflammation is increasingly recognized as a central driver of PD onset and progression in which oligodendrocytes, astrocytes, and microglia engage in complex bidirectional crosstalk that shapes the inflammatory milieu of the central nervous system. Pathological activation of glial cells triggers the release of pro-inflammatory cytokines, chemokines, and reactive oxygen species, thereby exacerbating neuronal injury and contributing to sustained disease progression. Modulating maladaptive glial activation states and their intercellular communication represents a promising therapeutic avenue aimed at mitigating neuroinflammation and slowing PD pathology. This review synthesizes current knowledge on neuroinflammation in PD, focusing on the distinct roles of microglia, astrocytes, and oligodendrocytes, their interaction networks, and emerging therapeutic strategies.
- 15 January 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (1) , 156
Top Cited PapersOpen AccessMicroglia, Astrocytes, and Oligodendrocytes in Parkinson’s Disease: Neuroinflammatory Crosstalk and Emerging Therapeutic Strategies
Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by the degeneration of dopaminergic neurons in the substantia nigra, resulting in cardinal motor symptoms such as tremor, rigidity, and bradykinesia. Neuroinflammation is increasingly recognized as a central driver of PD onset and progression in which oligodendrocytes, astrocytes, and microglia engage in complex bidirectional crosstalk that shapes the inflammatory milieu of the central nervous system. Pathological activation of glial cells triggers the release of pro-inflammatory cytokines, chemokines, and reactive oxygen species, thereby exacerbating neuronal injury and contributing to sustained disease progression. Modulating maladaptive glial activation states and their intercellular communication represents a promising therapeutic avenue aimed at mitigating neuroinflammation and slowing PD pathology. This review synthesizes current knowledge on neuroinflammation in PD, focusing on the distinct roles of microglia, astrocytes, and oligodendrocytes, their interaction networks, and emerging therapeutic strategies.